Please login to the form below

Not currently logged in
Email:
Password:

BRVO

This page shows the latest BRVO news and features for those working in and with pharma, biotech and healthcare.

NICE backs Bayer’s Eylea as first-line BRVO treatment

NICE backs Bayer’s Eylea as first-line BRVO treatment

NICE backs Bayer’ s Eylea as first-line BRVO treatment. Recommends visual impairment therapy over current laser treatment. ... Bayer's Eylea (aflibercept) has been recommended for use on the NHS in England and Wales as a first-line treatment for adults

Latest news

  • NICE gives Bayer's Elyea a provisional 'no' for first-line use NICE gives Bayer's Elyea a provisional 'no' for first-line use

    NICE gives Bayer's Elyea a provisional 'no' for first-line use. Company says recommendation goes against Royal College guidance for BRVO. ... NICE's next appraisal committee meeting on Eylea and its use in BRVO will take place in July, with final

  • Bayer's Eylea cleared for wider use in Europe Bayer's Eylea cleared for wider use in Europe

    macular oedema following branch retinal vein occlusion (BRVO), while more than 50% of patients in the Eylea arm gained at least three lines of vision. ... BRVO is a common cause of visual impairment in the elderly and is around three times more common

  • Germany's IQWiG delivers bad news for Bayer’s Eylea Germany's IQWiG delivers bad news for Bayer’s Eylea

    Bayer has also filed an application to extend the indications of its ophthalmic drug Eylea in Europe to include use in patients with branch retinal vein occlusion (BRVO), a leading cause

  • Bayer files eye drug Eylea for new use in EU Bayer files eye drug Eylea for new use in EU

    BRVO is around three times more common than CRVO so could provide a further fillip to growth momentum if approved. ... BRVO is a common retinal vascular disorder with an estimated 14 million people affected worldwide," said Joerg Moeller, head of global

  • NICE backs new use for Bayer’s Eylea NICE backs new use for Bayer’s Eylea

    Lucentis has a slightly expanded indication, which also covers branch retinal vein occlusion (BRVO), although only if treatment involving the use of lasers to seal blood vessels in the eye has

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics